ssgj-707

mAbexperimentalBi-specific

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07222800Phase 3Dec 12, 2025Pfizer
NCT07222566Phase 3Dec 5, 2025Pfizer
NCT07227415Phase 1/Phase 2 (Phase 2)Dec 4, 2025Pfizer
NCT07227012Phase 1/Phase 2 (Phase 2)Dec 1, 2025Pfizer
NCT07227298Phase 1/Phase 2 (Phase 2)Nov 17, 2025Pfizer
NCT07226999Phase 2/Phase 3 (Phase 3)Nov 17, 2025Pfizer
NCT06980272Phase 3Jun 20, 2025Sunshine Lake Pharma Co., Ltd.
NCT06522828Phase 2Oct 10, 2024Sunshine Lake Pharma Co., Ltd.
NCT06493760Phase 2Sep 3, 2024Sunshine Lake Pharma Co., Ltd.
NCT06412471Phase 2Jul 26, 2024Sunshine Lake Pharma Co., Ltd.
NCT06361927Phase 2May 15, 2024Sunshine Lake Pharma Co., Ltd.
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
PfizerFor profit6622025
Sunshine Lake Pharma Co., Ltd.For profit5522024
2 organizations
Page 1 / 1